# Advances in Immunotherapy of KRAS-mutated Non-small Cell Lung Cancer

## TL;DR

This paper reviews advances in immunotherapy for non-small cell lung cancer with KRAS mutations, focusing on immune checkpoint inhibitors and combination therapies.

## Contribution

The paper provides an updated overview of immunotherapy strategies and clinical outcomes for KRAS-mutated NSCLC.

## Key findings

- Immune checkpoint inhibitors show significant efficacy in improving survival for KRAS-mutated NSCLC patients.
- Combination immunotherapy approaches are being actively explored to enhance treatment outcomes.
- Challenges remain due to tumor microenvironment complexity and patient variability.

## Abstract

在流行病学统计中肺恶性肿瘤的发病率与致死率均位居前列。非小细胞肺癌（non-small cell lung cancer, NSCLC）是肺癌的重要组成部分，成为临床研究与治疗的重点关注对象。在NSCLC基因组学特征中，Kirsten大鼠肉瘤病毒基因同源物（Kirsten rat sarcoma viral oncogene homolog, KRAS）突变属于主要的肿瘤驱动因素之一，约占所有NSCLC病例的25%。该突变的存在与患者的治疗反应及预后密切相关，因此针对KRAS突变型NSCLC的治疗策略是肿瘤研究领域的重要课题。当前时代背景下，免疫调节治疗凭借其独特的作用机制与显著的临床疗效在肿瘤学领域快速普及并迅速发展，针对NSCLC KRAS驱动基因突变亚型的治疗策略逐渐成为研究热点。免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）的诞生，为这类癌症患者开辟了全新的治疗路径，临床研究显示其在改善生存期方面具有显著效果。然而，目前在免疫治疗的应用中仍面临诸多挑战，如肿瘤微环境的复杂性、患者个体差异及耐药机制等。本文综述了KRAS突变型NSCLC的免疫治疗进展，重点分析了免疫治疗的具体应用、联合疗法的探索及其相关临床试验结果，同时探讨了KRAS突变型NSCLC治疗未来可能的发展方向，为临床治疗实践提供参考。

Efficacy of immune checkpoint inhibitors in KRAS-mutanted NSCLC

Efficacy of immune combination therapy in KRAS-mutanted NSCLC